Research/Clinical Trial Information List of our current clinical trials: Novartis Trial (IPF) Looking for patients with idiopathic pulmonary fibrosis to participate in a Phase 2 placebo controlled, multiple dose, exploratory proof of concept study for QAX576, a full human monoclonal antibody.  6 minute walk test of  >50 meters at screening  Decline of FVC at least 5% in 12 month period  FEV1/FVC ratio has to be over 60%  FVC greater than or equal to 60%  DLCO >30%  Please contact Sara at slogie@gcrmweb.com for further details Summit HZC113782 Trial (COPD)  A clinical outcomes study to compare the effect of a once daily dose of Fluticasone Furoate/ Vilanterol (a long acting beta antagonist)Inhalation powder versus placebo on survival in subjects with stage 2 GOLD COPD and a history of or increased risk for cardiovascular disease  Ages 40-80  Greater or equal to 10 years cigarette history. Current or former smokers  Excluded: patients with severe heart failure, diagnosis of asthma, or other respiratory diseases/disorders, COPD exacerbation within 14 days,  Excluded: corticosteroids within 30 days, and patients using oxygen therapy for greater than 12 hours daily.  Patients will be seen in clinic every 12 weeks.  Patients will be paid for time and travel.  Please contact Linda at ltilme@gcrmweb.com for further details Ambition Trial (PAH) Looking for patients with Pulmonary Arterial Hypertension (PAH) to participate in study to compare combination therapy (ambrisentan and tadalafil) vs. initial monotherapy (ambrisentan or tadalafil).  There is no placebo in this study.  Ages 18-75  Must not have had previous PAH treatment within 4 weeks.  Patients will be paid for time and travel.  Please contact Linda at ltilme@gcrmweb.com for further details Prospect Registry (PAH) Looking for patients with Pulmonary Arterial Hypertension (PAH) to participate in registry.  Any and all patients receiving RTS Epoprostenol (Veletri)  Please contact Linda at ltilme@gcrmweb.com  for further details. PAH QuERI Registry (PAH) Looking at patient management over the course of 3 years. Information will be collected every 6 months using remote data entry platform.  Patient can be on ANY PAH Meds  Must have dx of PAH (less than 3 years duration)  WHO group One confirmed by RHC (mPAP > 25mm and PCWP £15)  FEV 1 > 50% and  V/Q and/or CT scan excluding thromboembolic etiology  Please contact Linda at email: ltilme@gcrmweb.com for further details Tyvaso Registry (PAH) Looking for patients to participate in observational study to assess respiratory tract adverse events in PAH patients treated with Tyvaso vs. other PAH therapy.  WHO group one  Prescribed any ANY PAH meds  Please contact Linda email ltilme@gcrmweb.com for further details FOREST ROF-MD-07 (COPD) Looking for patients with COPD to investigate the efficacy and safety of roflumilast on exacerbation rate in subjects treated with a fixed dose combination of long-acting beta antagonist and inhaled corticosteroid  At least 40 years old  Stage III and stage IV diagnosis of COPD by GOLD criteria  FEV1/FVC  <70%  FEV1  < or equal to 50%  At least 2 documented exacerbations in 12 months  Must be on Advair or Symbicort  Please contact Serteria ssanabria@gcrmweb.com for further details